Variable | Overall withdrawal | Withdrawal due to inefficacy | Withdrawal due to adverse events | |||
---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |
Demographic | ||||||
Age at start of therapy (years) | 0.99 (0.98 to 1.00) | 0.99 (0.98 to 1.00) | 0.99 (0.97 to 1.01) | 0.99 (0.96 to 1.01) | 0.98 (0.95 to 1.01) | 0.96 (0.93 to 1.00) |
Female | 1.38* (1.12 to 1.70) | 1.29* (1.01 to 1.65) | 1.48 (0.92 to 2.37) | 1.45 (0.82 to 2.64) | 1.64 (0.87 to 3.09) | 1.58 (0.78 to 3.22) |
Smoking (yes/no) | 1.36* (1.09 to 1.68) | 1.22 (0.96 to 1.55) | 1.70* (1.03 to 2.81) | 1.51 (0.87 to 2.64) | 1.10 (0.59 to 2.07) | 0.97 (0.49 to 1.89) |
Co-morbiditya (yes/no) | 1.77* (1.39 to 2.25) | 1.49* (1.13 to 1.96) | 1.64 (0.97 to 2.80) | 1.17 (0.64 to 2.12) | 2.68* (1.23 to 5.85) | 2.67* (1.16 to 6.15) |
Start year of therapyb | ||||||
2003 | 0.79 (0.56 to 1.13) | 0.95 (0.98 to 2.21) | 0.84 (0.37 to 1.95) | 0.99 (0.73 to 5.44) | 1.25 (0.42 to 3.72) | 0.92 (0.70 to 3.04) |
2004 | 0.65* (0.46 to 0.93) | 0.93 (0.87 to 2.03) | 0.71 (0.31 to 1.64) | 0.81 (0.64 to 5.12) | 0.70 (0.22 to 2.23) | 0.96 (0.44 to 5.49) |
2005 | 0.52* (0.34 to 0.80) | 0.93 (0.74 to 2.19) | 0.68 (0.26 to 1.79) | 0.92 (0.61 to 7.45) | 0.52 (0.13 to 2.19) | 0.95 (0.28 to 7.55) |
2006 | 0.43 (0.18 to 1.03) | 0.94 (0.73 to 2.12) | 0.99 (0.19 to 4.95) | 0.94 (0.62 to 6.64) | 0.99 (0.99 to 1.00) | 0.93 (0.28 to 5.65) |
Disease | ||||||
Baseline HAQ | 1.16* (1.03 to 1.29) | 1.08 (0.95 to 1.22) | 1.26* (1.02 to 1.55) | 1.20 (0.95 to 1.49) | 1.16 (0.83 to 1.62) | 1.06 (0.71 to 1.59) |
Disease duration (years) | 0.99 (0.98 to 1.00) | 0.99 (0.98 to 1.01) | 0.98 (0.95 to 1.00) | 0.99 (0.97 to 1.03) | 0.99 (0.96 to 1.03) | 0.99 (0.95 to 1.03) |
Baseline DAS-28 | 0.93 (0.85 to 1.01) | 0.88 (0.79 to 1.16) | 0.88 (0.73 to 1.07) | 0.83 (0.66 to 1.04) | 0.88 (0.69 to 1.12) | 0.89 (0.66 to 1.57) |
Inflammationc | 0.93 (0.74 to 1.15) | -- | 0.72 (0.45 to 1.17) | -- | 1.18 (0.60 to 2.29) | -- |
Tender joint counts | 1.00 (0.99 to 1.01) | -- | 0.99 (0.97 to 1.03) | -- | 1.00 (0.96 to 1.04) | -- |
Swollen joint counts | 0.97* (0.96 to 0.99) | -- | 0.98 (0.94 to 1.02) | -- | 0.99 (0.94 to 1.04) | -- |
Therapeutic – concurrent use of: | ||||||
Methotrexate | 0.89 (0.72 to 1.09) | 0.64 (0.49 to 1.12) | 1.03 (0.64 to 1.67) | 0.65 (0.36 to 1.18) | 1.06 (0.57 to 1.99) | 0.67 (0.32 to 1.39) |
Sulfasalazine | 0.49 (0.29 to 1.15) | 0.30 (0.13 to 1.19) | 0.40 (0.10 to 1.64) | 0.32 (0.04 to 2.36) | 0.68 (0.16 to 2.81) | 1.54 (0.34 to 6.92) |
Steroids | 1.22 (0.96 to 1.57) | 1.06 (0.81 to 1.38) | 1.14 (0.65 to 2.01) | 0.91 (0.49 to 1.71) | 1.89 (0.98 to 3.66) | 1.92 (0.95 to 3.89) |
Biological therapyd | ||||||
Infliximab | 2.30* (1.85 to 2.87) | 2.80* (2.12 to 3.70) | 2.62* (1.59 to 4.34) | 3.77* (1.96 to 7.24) | 2.42* (1.26 to 4.68) | 3.12* (1.41 to 6.89) |
Adalimumab | 1.11 (0.78 to 1.59) | 1.00 (0.67 to 1.51) | 1.81 (0.89 to 3.65) | 1.62 (0.70 to 3.78) | 1.11 (0.37 to 3.33) | 0.74 (0.21 to 2.66) |